

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/780,452	02/17/2004	Janel E. Young	ETH5123 1524	
27777 PHILIP S. JOI	7590 11/20/2007	EXAMINER		
JOHNSON &	JOHNSON	AZPURU, CARLOS A		
ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			ART UNIT	PAPER NUMBER
NEW BRONS			1615	
			MAIL DATE	DELIVERY MODE
			11/20/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application	No.	Applicant(s)				
Office Action Summary		10/780,452		YOUNG ET AL.				
		Examiner		Art Unit				
		Carlos A. Az	puru	1615				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Rep		(IO OFT TO	EVELOE - MONTHY	O) OD TUUDTY (20) DAYO				
WHICHEVE - Extensions of after SIX (6) M - If NO period for Failure to repl Any reply received.	NED STATUTORY PERIOD FOR REPLY IN INC.	ATE OF THIS 36(a). In no event, will apply and will ex, cause the applica	COMMUNICATION however, may a reply be tim xpire SIX (6) MONTHS from to become ABANDONEI	I. lely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status	·							
1)⊠ Respo	onsive to communication(s) filed on <u>29 O</u>	ctober 2007.						
2a) <u> </u>	This action is FINAL . 2b)⊠ This action is non-final.							
·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposition of	Claims							
4)⊠ Claim	(s) <u>14-19,21-24,27-37 and 39-41</u> is/are p	ending in the	application.					
4a) Of	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)∭ Claim	5) Claim(s) is/are allowed.							
·	S)⊠ Claim(s) <u>14,15,18,24,28,29,31-33 and 36</u> is/are rejected.							
· <u></u>	(s) <u>16,17,19,21-23,27,30,34,35,37 and 3</u>		•					
8) Claim	(s) are subject to restriction and/or	r election req	uirement.					
Application Pa	pers							
9)∐ The sp	pecification is objected to by the Examine	r.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applic	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under	35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
1. Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
				·				
Attachment(s)								
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date								
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application								
Paper No(s)/Mail Date <u>2172004 & 08152005</u> . 6)								

Application/Control Number: 10/780,452

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of the information disclosure statements filed 02/17/2004 and 08/15/2005. An election was originally filed on 08/30/2007. A preliminary amendment and supplemental election was filed on 10/29/2007.

Election/Restrictions

Applicant's election without traverse of Group II (claims 14-19, 21-24, 27-37, 39-41) in the reply filed on 10/29/2007 is acknowledged.

Claims 1-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 10/29/2007.

Claim Objections

Claims 22 and 40 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim.

Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

The independent claims already set out an effective amount which inhibits formation of adhesions. Claims 22 and 40 therefore fail to further limit the invention.

Application/Control Number: 10/780,452

Art Unit: 1615

Claim Rejections - 35 USC § 112

Claims 32 and 33 recite the limitation "burst/sustained release" in claim 28.

There is insufficient antecedent basis for this limitation in the claim.

Solutions do not provide support for sustained release. Correction is required.

Claims 22,23, 40 and 41 recites the limitation "a further therapeutic agent" in claims 14 and 28. There is insufficient antecedent basis for this limitation in the claim.

Claims 14 and 28 do not set out a further bioactive. Correction is requested.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Application/Control Number: 10/780,452

Art Unit: 1615

Claims 14, 15, 18, 24, 28, 29, 31 and 36 are rejected under 35 U.S.C. 102(b) as being anticipated by Morita et al.

Morita et al disclose a Pemirolast solution used for allergic conjunctivitis (see Abstract; col. 1, lines 35-66; col. 2, lines 32 – 45. The solution is a phosphate buffered saline (see formulations B –F, cols. 3-4). Solutions are single does delivery systems. Intended use is not given patentable weight in compositions. The instant claims are anticipated by Morita et al.

Claims 16, 17, 19, 21-23, 27, 30, 34, 35, 37, 39-41 are objected to dependent upon a rejected base claim.

Advanced Consumer Information on Pemirolast is cited as pertinent art.

Rxlist.com (page 5) is cited for its teaching of proper dosage for Pemirolast (Alamast).

PDR is cited for its teaching that the dosage claimed is within that found for its known use in ophthalmic solutions (See page 3).

Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlos A. Azpuru whose telephone number is (571) 272-0588. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000

Primary Examiner

Art Unit 1615